Market Summary
USD0.89-0.04
Market Closed-4.29%
GOSS Stock Price
GOSS RSI Chart
GOSS Valuation
GOSS Price/Sales (Trailing)
GOSS Profitability
GOSS Fundamentals
GOSS Revenue
GOSS Earnings
Price Action
52 Week Range
0.8413.68
(Low)(High)
Last 7 days
-1.7%
Last 30 days
-7.6%
Last 90 days
-28.8%
Trailing 12 Months
-93.1%
GOSS Financial Health
GOSS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for GOSS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-07-24 | Hasnain Faheem | acquired | 983,120 | 1.82 | 540,176 | president & ceo |
2023-07-24 | Christian Waage | acquired | 24,577 | 1.82 | 13,504 | evp, tech ops and admin |
2023-07-24 | Giraudo Bryan | acquired | 98,316 | 1.82 | 54,020 | coo/cfo |
2023-06-22 | Aranda Richard | sold | -2,340 | 1.29 | -1,814 | chief medical officer |
2023-04-04 | Giraudo Bryan | bought | 56,094 | 1.0199 | 55,000 | coo/cfo |
2023-03-22 | Hasnain Faheem | bought | 503,580 | 1.1432 | 440,500 | president & ceo |
2023-03-21 | Hasnain Faheem | bought | 322,324 | 1.1965 | 269,389 | president & ceo |
2023-03-20 | Hasnain Faheem | bought | 174,486 | 1.0344 | 168,683 | president & ceo |
2023-03-20 | Christian Waage | bought | 22,144 | 1.197 | 18,500 | evp, tech ops and admin |
2023-03-20 | Giraudo Bryan | bought | 48,435 | 0.9687 | 50,000 | coo/cfo |
Which funds bought or sold GOSS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-23 | WOLVERINE TRADING, LLC | new | - | 29,399 | 29,399 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | sold off | -100 | -29,504 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -64.91 | -717 | 360 | -% |
2023-08-16 | CreativeOne Wealth, LLC | added | 104 | 274,000 | 314,000 | 0.01% |
2023-08-15 | GOLDMAN SACHS GROUP INC | reduced | -69.68 | -1,193,460 | 484,641 | -% |
2023-08-15 | Ground Swell Capital, LLC | sold off | -100 | -16,931 | - | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | reduced | -92.39 | -14,807 | 1,157 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | reduced | -29.08 | -85,504 | 177,924 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | unchanged | - | - | - | -% |
2023-08-14 | CITADEL ADVISORS LLC | reduced | -48.96 | -1,809,580 | 1,711,760 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Gossamer Bio
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jul 28, 2023 | growth equity opportunities 18 vge, llc | 8.2% | 18,793,076 | SC 13D | |
| May 10, 2023 | state street corp | 1.39% | 1,319,485 | SC 13G/A | |
| May 05, 2023 | blackrock inc. | 4.9% | 4,653,619 | SC 13G/A | |
| Feb 14, 2023 | hhlr advisors, ltd. | 5.3% | 4,974,041 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.43% | 7,959,857 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 5.7% | 5,413,023 | SC 13G/A | |
| Jan 10, 2023 | state street corp | 29.47% | 27,843,985 | SC 13G | |
| Jan 04, 2023 | millennium management llc | 5.1% | 4,804,301 | SC 13G | |
| Dec 20, 2022 | millennium management llc | 3.6% | 3,370,562 | SC 13G | |
| Feb 03, 2022 | blackrock inc. | 7.1% | 5,429,686 | SC 13G/A |
Recent SEC filings of Gossamer Bio
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 07, 2023 | 8-K | Current Report | |
| Aug 28, 2023 | EFFECT | EFFECT | |
| Aug 28, 2023 | 424B3 | Prospectus Filed | |
| Aug 21, 2023 | DEL AM | DEL AM | |
| Aug 18, 2023 | RW | RW | |
| Aug 18, 2023 | S-3 | S-3 | |
| Aug 17, 2023 | S-3ASR | S-3ASR | |
| Aug 08, 2023 | 8-K | Current Report | |
| Aug 08, 2023 | 10-Q | Quarterly Report | |
| Aug 07, 2023 | D | D |
Peers (Alternatives to Gossamer Bio)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 145.2B | 26.6B | 0.95% | 16.34% | 18.2 | 5.46 | 0.75% | 21.34% |
GILD | 94.5B | 27.4B | -0.14% | 17.18% | 17.24 | 3.45 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | 5.04% | -16.54% | 32.68 | 3.7 | -53.67% | -91.41% |
BIIB | 37.7B | 10.0B | -1.72% | 22.66% | 14.15 | 3.78 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 7.33% | 6.48% | 63.52 | 6.7 | 29.01% | 1345.90% |
BBIO | 4.5B | - | -2.02% | 149.47% | -7.78 | 48.33 | 54.84% | -12.96% |
DNLI | 3.0B | - | -2.17% | -26.37% | -23.64 | 37.44 | 122.90% | 54.78% |
BEAM | 1.9B | 80.2M | 4.97% | -54.45% | -5.84 | 23.83 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | 6.99% | -20.27% | -5.28 | 12.52 | -70.36% | -531.73% |
REPL | 1.1B | 15.3M | -8.28% | 9.52% | -5.79 | 68.68 | 1090.59% | -36.57% |
NVAX | 664.9M | 1.6B | 7.56% | -72.99% | -1.13 | 0.42 | 23.74% | 60.24% |
FATE | 231.5M | - | -15.47% | -90.72% | -1.09 | 1.69 | 116.83% | 16.61% |
SGMO | 147.4M | - | -7.75% | -84.08% | -0.74 | 0.61 | 113.96% | -15.19% |
VXRT | 112.7M | 2.1M | -0.08% | -70.69% | -1.12 | 54.83 | 487.70% | -8.66% |
IBIO | 4.1M | - | -18.13% | -96.55% | -0.05 | 3.21 | - | -129.46% |
Gossamer Bio News
Returns for GOSS
Cumulative Returns on GOSS
-58.6%
3-Year Cumulative Returns
Risks for GOSS
What is the probability of a big loss on GOSS?
96.3%
Probability that Gossamer Bio stock will be more than 20% underwater in next one year
85.6%
Probability that Gossamer Bio stock will be more than 30% underwater in next one year.
68.3%
Probability that Gossamer Bio stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does GOSS drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Gossamer Bio was unfortunately bought at previous high price.
Drawdowns
Financials for Gossamer Bio
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2021Q4 | 2020Q4 | 2019Q4 | 2018Q4 |
| Revenue | 108.0% | 1,583,000 | 761,000 | 3,442,000 | 5,563,000 | 1,720,000 |
| Operating Expenses | 1.1% | 218,593,000 | 216,124,000 | 233,962,000 | 186,139,000 | 148,993,000 |
| S&GA Expenses | 4.0% | 47,609,000 | 45,782,000 | 49,728,000 | 39,136,000 | 44,051,000 |
| EBITDA | 100.0% | - | -212,816,000 | -229,285,000 | -177,452,000 | -146,660,000 |
| EBITDA Margin | 100.0% | - | -279 | -66.61 | -31.90 | -85.27 |
| Interest Expenses | -28.6% | 13,880,000 | 19,440,000 | 12,666,000 | 1,938,000 | 12,000 |
| EBT Margin | 100.0% | - | -307 | -70.70 | -32.41 | -85.45 |
| Net Income | 2.0% | -229,378,000 | -234,004,000 | -243,360,000 | -180,307,000 | -146,969,000 |
| Net Income Margin | 52.9% | -144 | -307 | -70.70 | -32.41 | - |
| Free Cashflow | 1.6% | -187,442,000 | -190,436,000 | -177,863,000 | -147,800,000 | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
| Assets | -17.4% | 182 | 220 | 272 | 324 | 246 | 295 | 344 | 387 | 433 | 482 | 539 | 584 | 625 | 371 | 427 | 470 | 507 | 516 | 239 |
| Current Assets | -17.6% | 173 | 210 | 262 | 312 | 233 | 281 | 332 | 374 | 417 | 466 | 522 | 566 | 608 | 355 | 409 | 452 | 490 | 498 | 232 |
| Cash Equivalents | -43.3% | 37.00 | 65.00 | 112 | 153 | 94.00 | 139 | 183 | 214 | 343 | 440 | 487 | 462 | 486 | 111 | 135 | 131 | 149 | 171 | 105 |
| Net PPE | -13.1% | 3.00 | 4.00 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 4.00 | 3.00 |
| Liabilities | -1.5% | 245 | 248 | 260 | 267 | 262 | 265 | 222 | 217 | 212 | 210 | 219 | 212 | 205 | 65.00 | 74.00 | 71.00 | 66.00 | 36.00 | 21.00 |
| Current Liabilities | -1.1% | 40.00 | 41.00 | 49.00 | 53.00 | 44.00 | 35.00 | 40.00 | 36.00 | 30.00 | 29.00 | 39.00 | 33.00 | 28.00 | 28.00 | 37.00 | 33.00 | 28.00 | 25.00 | 20.00 |
| LT Debt, Current | 0% | 12.00 | 12.00 | 12.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| LT Debt, Non Current | -30.2% | 6.00 | 9.00 | 12.00 | 15.00 | 18.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | - | - |
| Shareholder's Equity | -120.7% | -62.80 | -28.46 | 12.00 | 56.00 | -16.46 | 30.00 | 121 | 170 | 221 | 272 | 321 | 372 | 420 | 306 | 352 | 399 | 441 | 480 | - |
| Retained Earnings | -3.9% | -1,123 | -1,081 | -1,032 | -976 | -917 | -860 | -811 | -755 | -695 | -635 | -577 | -512 | -455 | -388 | -334 | -279 | -230 | -186 | -153 |
| Additional Paid-In Capital | 0.8% | 1,062 | 1,053 | 1,045 | 1,033 | 901 | 891 | 933 | 925 | 915 | 907 | 898 | 885 | 875 | 695 | 686 | 678 | 672 | 667 | 34.00 |
| Shares Outstanding | 0.0% | 95.00 | 95.00 | 94.00 | 94.00 | 77.00 | 76.00 | 76.00 | 75.00 | 75.00 | 74.00 | 74.00 | 72.00 | 67.00 | 62.00 | 62.00 | 53.00 | 60.00 | 36.00 | 7.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 5.7% | -175 | -186 | -187 | -179 | -184 | -183 | -188 | -185 | -188 | -182 | -176 | -183 | -174 | -169 | -144 | -125 | -105 | -75.11 | -51.04 | -34.69 | -21.01 |
| Share Based Compensation | -4.5% | 38.00 | 40.00 | 43.00 | 39.00 | 36.00 | 34.00 | 32.00 | 37.00 | 38.00 | 39.00 | 39.00 | 33.00 | 30.00 | 26.00 | 21.00 | 25.00 | 37.00 | 33.00 | 31.00 | 27.00 | 4.00 |
| Cashflow From Investing | 1126.5% | 8.00 | -0.73 | -1.03 | 1.00 | -66.22 | -120 | -117 | -66.77 | 43.00 | 199 | 215 | 201 | 199 | 79.00 | -147 | -202 | -325 | -353 | -144 | -181 | -61.83 |
| Cashflow From Financing | -2.6% | 111 | 114 | 117 | 120 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 313 | 313 | 314 | 313 | 31.00 | 322 | 318 | 547 | 520 | 301 | 404 | 147 |
GOSS Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Operating expenses: | ||||
| Research and development | $ 36,309 | $ 42,580 | $ 74,104 | $ 84,902 |
| In process research and development | 15 | 15 | 30 | 35 |
| General and administrative | 9,976 | 11,277 | 20,108 | 23,278 |
| Total operating expenses | 46,300 | 53,872 | 94,242 | 108,215 |
| Loss from operations | (46,300) | (53,872) | (94,242) | (108,215) |
| Other income (expense) | ||||
| Interest income | 695 | 300 | 1,282 | 524 |
| Interest expense | (3,429) | (3,481) | (6,929) | (6,948) |
| Other income, net | 6,538 | 587 | 8,228 | 388 |
| Total other income (expense), net | 3,804 | (2,594) | 2,581 | (6,036) |
| Net loss | (42,496) | (56,466) | (91,661) | (114,251) |
| Other comprehensive income (loss): | ||||
| Foreign currency translation | 1 | (138) | 24 | (146) |
| Unrealized gain (loss) on marketable securities | (46) | (36) | 69 | (413) |
| Other comprehensive income (loss) | (45) | (174) | 93 | (559) |
| Comprehensive loss | $ (42,541) | $ (56,640) | $ (91,568) | $ (114,810) |
| Net loss per share, basic (in dollars per share) | $ (0.45) | $ (0.74) | $ (0.96) | $ (1.50) |
| Net loss per share, diluted (in dollars per share) | $ (0.45) | $ (0.74) | $ (0.96) | $ (1.50) |
| Weighted average common shares outstanding, basic (in shares) | 95,446,929 | 76,668,162 | 95,160,204 | 76,283,564 |
| Weighted average common shares outstanding, diluted (in shares) | 95,446,929 | 76,668,162 | 95,160,204 | 76,283,564 |
GOSS Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 37,004 | $ 111,973 |
| Marketable securities | 125,122 | 143,705 |
| Prepaid expenses and other current assets | 11,250 | 6,202 |
| Total current assets | 173,376 | 261,880 |
| Property and equipment, net | 3,054 | 3,981 |
| Operating lease right-of-use assets | 4,546 | 5,909 |
| Other assets | 770 | 680 |
| Total assets | 181,746 | 272,450 |
| Current liabilities | ||
| Accounts payable | 2,205 | 1,459 |
| Accrued research and development expenses | 12,062 | 15,626 |
| Current portion of long-term debt | 11,613 | 11,613 |
| Accrued expenses and other current liabilities | 14,260 | 20,532 |
| Total current liabilities | 40,140 | 49,230 |
| Long-term convertible senior notes | 196,144 | 195,709 |
| Debt, non-current portion | 6,436 | 11,988 |
| Operating lease liabilities - long-term | 1,826 | 3,446 |
| Total liabilities | 244,546 | 260,373 |
| Commitments and contingencies (Note 9) | ||
| Stockholders' equity (deficit) | ||
| Common stock, $0.0001 par value; 700,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 95,452,703 shares issued and outstanding as of June 30, 2023, and 94,478,405 shares issued and 94,423,181 shares outstanding as of December 31, 2022 | 10 | 10 |
| Additional paid-in capital | 1,061,555 | 1,044,864 |
| Accumulated deficit | (1,123,884) | (1,032,223) |
| Accumulated other comprehensive loss | (481) | (574) |
| Total stockholders' equity (deficit) | (62,800) | 12,077 |
| Total liabilities and stockholders' equity (deficit) | $ 181,746 | $ 272,450 |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.